Navigation Links
Total Artificial Heart Manufacturer SynCardia Secures $19M Financing
Date:3/20/2013

TUCSON, Ariz., March 20, 2013 /PRNewswire/ -- SynCardia Systems, Inc. (www.syncardia.com), the privately-held manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today the raise of $19 million of long-term growth capital, including a $15 million structured financing from Athyrium Opportunities Fund, as well as a $4 million follow-on equity investment from existing shareholders.

(Photo: http://photos.prnewswire.com/prnh/20130320/LA80277)

"The proceeds will help support commercialization of our Freedom® portable driver*, the world's first wearable power supply for the SynCardia temporary Total Artificial Heart, and accelerate the launch of our new, smaller 50cc Total Artificial Heart**, designed for patients of smaller stature, including women and adolescents," said Michael Garippa , SynCardia Chairman/CEO/President. "In 2012, we generated $25 million in revenue and a record-breaking 125 implants at more than 50 SynCardia Certified Centers worldwide."

"SynCardia's recent growth is likely the beginning of a longer-term trend," said Laurent Hermouet, a Partner of Athyrium. "The Total Artificial Heart will soon be able to address the entire biventricular heart failure market thanks to newer offerings like the Freedom driver as well as the 50cc version of the Total Artificial Heart. This broader product offering coupled with convincing clinical and INTERMACS data makes partnering with SynCardia a compelling opportunity. We look forward to expanding this initial relationship as might be needed in upcoming quarters."

SynCardia is an innovative, 85-employee company focused on advanced medical technology targeting the NYHA Class IV heart failure market. The company certifies and supports the top transplant centers around the world, including Texas Heart Institute in Houston, Cedars-Sinai in Los Angeles, Cincinnati Children's Hospital Medical Center, La Pitie Hospital in Paris and the Heart & Diabetes Center NRW in Bad Oeynhausen, Germany. There are currently 80 SynCardia Certified Centers worldwide with an additional 32 hospitals undergoing the company's four-phase certification program.

Athyrium Opportunities Fund ("Athyrium") is a New York-based fund focusing on investment opportunities in the global healthcare sector. The Athyrium investment team has substantial healthcare investment experience across a wide range of asset classes, including public equity, private equity, fixed income, royalties, and other structured securities. Athyrium invests across healthcare verticals, including biopharma, medical devices and products, and healthcare services. The team partners with management teams to implement creative financing solutions to companies' capital needs. For more information, please visit www.athyrium.com.

*CAUTION – The Freedom portable driver is an investigational device, limited by United States law to investigational use.

**In January, the U.S. Food and Drug Administration (FDA) approved two Humanitarian Use Device (HUD) designations for SynCardia's smaller 50cc Total Artificial Heart to be used for destination therapy and pediatric bridge to transplant. The next step is for SynCardia to submit a Humanitarian Device Exemption application for each indication to the FDA for approval. Once approved, the HDEs will allow up to 4,000 U.S. patients annually to receive the 50cc Total Artificial Heart as destination therapy, and an additional 4,000 pediatric patients to receive the device as a bridge to transplant.

About the SynCardia temporary Total Artificial Heart
SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, the SynCardia Total Artificial Heart is currently approved as a bridge to transplant for people suffering from end-stage heart failure affecting both sides of the heart (biventricular failure). There have been more than 1,100 implants of the Total Artificial Heart, accounting for more than 300 patient years of life.

Similar to a heart transplant, the SynCardia Total Artificial Heart replaces both failing heart ventricles and the four heart valves, eliminating the symptoms and source of end-stage biventricular failure. Unlike a donor heart, the Total Artificial Heart is immediately available at SynCardia Certified Centers. It is the only device that provides immediate, safe blood flow of up to 9.5 liters per minute through each ventricle. This high volume of safe blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.

Forbes Ranks SynCardia #69 Among "America's Most Promising Companies"
In its February 2013 issue, Forbes selected SynCardia as one of "America's Most Promising Companies" for the second consecutive year. On the list of 100 privately held, high-growth companies with bright futures, SynCardia was selected #69, moving up eight spots from its #77 ranking last year. See the full list of SynCardia Awards & Recognition here.

For additional information, please visit: http://www.syncardia.com
Like SynCardia on Facebook - http://www.facebook.com/pages/SynCardia-Systems-Inc/191245900926019   
Follow SynCardia on Twitter – http://twitter.com/SynCardia


'/>"/>
SOURCE SynCardia Systems, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Amedica Expands Patent Portfolio with Proprietary Silicon Nitride Total Disc Implant to Treat Neck and Back Pain
2. SynCardias 50cc Total Artificial Heart Receives Two HUD Designations from the FDA for Destination Therapy and Pediatric Bridge to Transplant
3. Ochsner Implants First Total Artificial Heart In The Gulf South Region
4. SynCardia Total Artificial Heart Patient with End-Stage Renal Failure Recovers Kidney Function after Two Months of Support
5. Total 3D Solutions Introduces Cinema ProMED System to Create Immersive Video Experiences for Dental Patients
6. University of Washington Leads All SynCardia Certified Centers with 10 Implants of the Total Artificial Heart in 2012
7. TriReme Announces a New Round of Financing Totalling US$18 Million
8. Computer-navigated total knee replacement provides no advantage over traditional surgical procedure
9. New Total Joint Replacement Registry From Remedy Informatics Aims to Enable Orthopedic Outcomes Research and Improve Quality for Hospitals and Orthopedic Surgery Groups
10. Regulus Announces $80.9 Million in Total Gross Proceeds from IPO and Other Recent Financial Transactions
11. Hanger, Inc. Announces 2012 Year To Date Acquisitions Totaling $35.6 Million Of Annual Net Revenue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 2016  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ) ... development of a once-daily, oral therapy for the treatment ... Officer, Dr. Maya Halpern , has notified the Company ... Officer and from its Board of Directors effective as ... age. Allen Baharaff . Mr. Baharaff continued, ...
(Date:2/11/2016)... Germany , February 11, 2016 ... up 6.8% to EUR 1,377.2m  Adjusted EBITDA climbs to ... 18.0% to EUR 3.41  Proposed dividend of EUR 0.85 ... sale of glass tubing business and refinancing successfully completed  ... to 5% on organic basis  Adjusted EBITDA expected ...
(Date:2/10/2016)... in the U.S. and Europe , announced ... laser at the upcoming 151 st Midwinter Meeting of ... #4815. The ST PRO is a full featured hard and ... the award winning, industry leading Lightwalker ATS. At an introductory price ... attractive to many dentists hesitating to incorporate lasers into their ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... ... as the World Molecular Imaging Congress (WMIC), will be held in New York ... meeting is “Imaging Biology…Improving Therapy.” The congress will highlight and emphasize how imaging ...
(Date:2/10/2016)... California (PRWEB) , ... February 10, 2016 , ... ... are working together to expand dental health services to the developmentally disabled in ... We Care Dental’s operations to a new facility at 71-949 Highway 111, Suite ...
(Date:2/10/2016)... ... February 10, 2016 , ... Compliancy Group LLC ... of medical professionals throughout the country. The Guard was specifically designed to handle ... procedures, employee training, regulatory updates, and compliance coaching. , In addition to meeting ...
(Date:2/10/2016)... , ... February 10, 2016 , ... Dr. Jessica Barron, ... practice is now accepting new dental patients and families in the North Metro Denver ... care services from cleanings to cosmetic dentistry, and all in the most relaxing environment. ...
(Date:2/10/2016)... ... ... AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the ... ended December 31, 2015 on Monday, February 29, 2016 after the market closes. , ... the release at 4:30 PM ET. Investors interested in participating by phone are invited ...
Breaking Medicine News(10 mins):